| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- Q203
-
- $1.00
-
2019-07-06
- CAS:1334719-95-7
- Min. Order: 1KG
- Purity: 98-100%
- Supply Ability: 1000kg
|
| Product Name: | Q203 | | Synonyms: | Q203;6-chloro-2-ethyl-N-[(4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}phenyl)methyl]imidazo[1,2-a]pyridine-3-carboxamide;6-CHLORO-2-ETHYL-N-(4-(4-(4-(TRIFLUOROMETHOXY)PHENYL)PIPERIDIN-1-YL)BENZYL)IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE;Q203（IAP6）;CS-2499;IAP 6;IAP6;IAP-6 | | CAS: | 1334719-95-7 | | MF: | C29H28ClF3N4O2 | | MW: | 557.01 | | EINECS: | | | Product Categories: | | | Mol File: | 1334719-95-7.mol |  |
| density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 16 mg/ml; DMSO: 14 mg/ml; Ethanol: Slightly soluble | | form | A solid | | pka | 12.29±0.46(Predicted) | | color | White to off-white | | InChIKey | OJICYBSWSZGRFB-UHFFFAOYSA-N | | SMILES | C12=NC(CC)=C(C(NCC3=CC=C(N4CCC(C5=CC=C(OC(F)(F)F)C=C5)CC4)C=C3)=O)N1C=C(Cl)C=C2 |
| Uses | Telacebec (Q203) is a midazopyridine amide compound. Telacebec is active against Mycobacterium tuberculosis H37Rv with an MIC50 of 2.7 nM in culture broth medium. | | in vivo | Telacebec (Q203) is efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight. Telacebec displays pharmacokinetic and safety profiles compatible with once-daily dosing. Telacebec has a bioavailability of 90% and a terminal half-life of 23.4 h. The volume of distribution is moderate (5.27 l per kg body weight), and the systemic clearance is low (4.03 mL/min per kg). After 4 weeks of treatment, reductions of 90%, 99% and 99.9% in M. tuberculosis H37Rv bacterial load is observed in the groups treated with Telacebec at 0.4, 2 and 10 mg per kg body weight, respectively[1]. | | References | [1] Pethe K, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med. 2013 Sep;19(9):1157-60. DOI:10.1038/nm.3262 |
| | Q203 Preparation Products And Raw materials |
|